Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.775 +0.025 (+0.67%)

Streaming Delayed Price Updated: 10:34 AM EDT, Jul 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Editas Medicine: Q1 Earnings Insights ↗

May 04, 2022

Editas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 28, 2022

Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to...

Via Benzinga

Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia ↗

April 26, 2022

The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia from leading...

Via Benzinga

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents ↗

March 01, 2022

The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

27 Stocks Moving in Monday's Pre-Market Session ↗

March 01, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) rose 28.6...

Via Benzinga

Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗

February 28, 2022

Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.

Via Investor's Business Daily

Expert Ratings For Editas Medicine ↗

February 25, 2022

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Editas Suddenly Terminates Chief Medical Officer Without An Explanation ↗

February 08, 2022

Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company.

Via Benzinga

51 Biggest Movers From Yesterday ↗

February 09, 2022

Also check out this: Apple And 3 Other Stocks Sold By Insiders Losers SelectQuote, Inc. (NYSE: SLQT) shares tumbled 47.3% to close at $3.44 on Tuesday after the company...

Via Benzinga

35 Stocks Moving In Tuesday's Mid-Day Session ↗

February 08, 2022

Gainers Society Pass Incorporated (NASDAQ: SOPA) gained 63.4% to $3.45 after dropping 16% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) climbed 56.1% to $3.45 following...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 08, 2022

Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $59...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 08, 2022

Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

21 Stocks Moving in Tuesday's Pre-Market Session ↗

February 08, 2022

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out this: Moderna And 4 Other Stocks Sold By...

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗

January 10, 2022

The companies hope to cure diseases of the liver, muscle and central nervous system.

Via Investor's Business Daily

Stocks Hitting New 52-Week Lows Today ↗

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗

December 22, 2021

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Via InvestorPlace

NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today ↗

December 13, 2021

Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR).

Via InvestorPlace

BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today ↗

December 13, 2021

BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937.

Via InvestorPlace

EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today ↗

December 13, 2021

After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.

Via InvestorPlace

22 Stocks Moving in Monday's Pre-Market Session ↗

December 13, 2021

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose...

Via Benzinga

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript ↗

November 08, 2021

EDIT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Why Editas Medicine Stock Is Jumping Today ↗

November 08, 2021

The gene-editing biotech company provided its Q3 update.

Via The Motley Fool

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.